High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and leukemia group B 9351

Keyphrases

• Phase II Study 100%
• Leukemia 100%
• High Dose 100%
• Initial Treatment 100%
• Aggressive non-Hodgkin Lymphoma 100%
• Doxorubicin 66%
• Cyclophosphamide 66%
• Aggressive Lymphoma 66%
• Phase II Trial 33%
• Dose Escalation 33%
• Lymphoma 33%
• Prednisone 33%
• Previously Untreated 33%
• Cause of Death 33%
• Prophylactic Antibiotics 33%
• Granulocyte Colony-stimulating Factor (G-CSF) 33%
• Relapsed Lymphoma 33%
• Thrombocytopenia 33%
• Continuous Infusion 33%
• Neutropenia 33%
• Serious Infection 33%
• Cell Killing 33%
• Intermediate Risk 33%
• Overall Survival 33%
• Response Rate 33%
• Toxicity Profile 33%
• Overall Response Rate 33%
• Failure-free Survival 33%
• International Prognostic Index 33%
• 4-cycle 33%
• Treatment-related Mortality 33%
• Mesna 33%
• Cycle Dose 33%

Medicine and Dentistry

• Malignant Neoplasm 100%
• Drug Megadose 100%
• Non-Hodgkin Lymphoma 100%
• CHOP 100%
• Leukemia 100%
• Cyclophosphamide 66%
• Aggressive Lymphoma 66%
• Doxorubicin 66%
• Acute Myelogenous Leukemia 33%
• Infection 33%
• Antibiotics 33%
• Myelodysplastic Syndrome 33%
• Phase II Trials 33%
• Neutropenia 33%
• Granulocyte Colony Stimulating Factor 33%
• Continuous Infusion 33%
• Overall Survival 33%
• Failure Free Survival 33%
• International Prognostic Index 33%
• Vincristine 33%
• Thrombocytopenia 33%
• Log Cell Kill 33%
• Prednisone 33%
• Coenzyme M 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Doxorubicin 100%
• Leukemia 100%
• Malignant Neoplasm 100%
• Cyclophosphamide 100%
• Nonhodgkin Lymphoma 100%
• Phase II Trials 50%
• Antibiotics 50%
• Coenzyme M 50%
• Infection 50%
• Granulocyte Colony Stimulating Factor 50%
• Overall Survival 50%
• Failure Free Survival 50%
• Prednisone 50%
• Myelodysplastic Syndrome 50%
• Thrombocytopenia 50%
• Neutropenia 50%
• Vincristine 50%